Clinical Characteristics of Patients With Advanced Hepatocellular Carcinoma Who Transitioned to Subsequent Therapies Following Systemic Therapy.
[AIM] This study aimed to clarify the clinical characteristics of patients with advanced hepatocellular carcinoma (HCC) who transitioned to subsequent therapies following systemic therapy (ST).
- 표본수 (n) 66
- p-value p < 0.001
APA
Imai K, Takai K, et al. (2026). Clinical Characteristics of Patients With Advanced Hepatocellular Carcinoma Who Transitioned to Subsequent Therapies Following Systemic Therapy.. Cancer medicine, 15(2), e71616. https://doi.org/10.1002/cam4.71616
MLA
Imai K, et al.. "Clinical Characteristics of Patients With Advanced Hepatocellular Carcinoma Who Transitioned to Subsequent Therapies Following Systemic Therapy.." Cancer medicine, vol. 15, no. 2, 2026, pp. e71616.
PMID
41656177
Abstract
[AIM] This study aimed to clarify the clinical characteristics of patients with advanced hepatocellular carcinoma (HCC) who transitioned to subsequent therapies following systemic therapy (ST).
[METHODS] In total, 136 patients with unresectable HCC (26 hepatitis B, 47 hepatitis C and 63 others) receiving first-line ST, including 31 patients treated with immune checkpoint inhibitors (ICIs), were enrolled. Clinical characteristics and adverse events observed during treatment, as well as overall survival (OS), progression-free survival and post progression survival (PPS), were compared between patients who transitioned to subsequent therapies (2nd therapy group, n = 66) and those who did not (non-2nd therapy group, n = 70).
[RESULTS] Significant differences between the two groups were observed in OS (29.3 vs. 10.7 months, p < 0.001), PPS (11.3 vs. 2.9 months, p < 0.001), ALBI score (-2.48 vs. -2.34, p = 0.018), treatment with/without ICIs (24/42 vs. 7/63, p < 0.001), TNM stage (II/III/IVA/IVB; 15/26/7/18 vs. 3/27/10/30, p = 0.008) and the adverse events of appetite loss (p = 0.009) and proteinuria (p = 0.006). A favourable ALBI score (p = 0.005), treatment with ICIs (p = 0.002) and earlier TNM stage (p = 0.027) identified by logistic regression analysis and TNM stage II in men and prothrombin time ≥ 105% in women by classification tree analysis were found to be associated with a higher likelihood of transitioning to subsequent therapies.
[CONCLUSIONS] Initiating systemic therapy, including ICIs, before clinical stage progression and preserving the hepatic reserve is crucial for ensuring a smooth transition to subsequent therapies. REGISTRY AND THE REGISTRATION NO.
[OF THE STUDY/TRIAL] N/A.
[METHODS] In total, 136 patients with unresectable HCC (26 hepatitis B, 47 hepatitis C and 63 others) receiving first-line ST, including 31 patients treated with immune checkpoint inhibitors (ICIs), were enrolled. Clinical characteristics and adverse events observed during treatment, as well as overall survival (OS), progression-free survival and post progression survival (PPS), were compared between patients who transitioned to subsequent therapies (2nd therapy group, n = 66) and those who did not (non-2nd therapy group, n = 70).
[RESULTS] Significant differences between the two groups were observed in OS (29.3 vs. 10.7 months, p < 0.001), PPS (11.3 vs. 2.9 months, p < 0.001), ALBI score (-2.48 vs. -2.34, p = 0.018), treatment with/without ICIs (24/42 vs. 7/63, p < 0.001), TNM stage (II/III/IVA/IVB; 15/26/7/18 vs. 3/27/10/30, p = 0.008) and the adverse events of appetite loss (p = 0.009) and proteinuria (p = 0.006). A favourable ALBI score (p = 0.005), treatment with ICIs (p = 0.002) and earlier TNM stage (p = 0.027) identified by logistic regression analysis and TNM stage II in men and prothrombin time ≥ 105% in women by classification tree analysis were found to be associated with a higher likelihood of transitioning to subsequent therapies.
[CONCLUSIONS] Initiating systemic therapy, including ICIs, before clinical stage progression and preserving the hepatic reserve is crucial for ensuring a smooth transition to subsequent therapies. REGISTRY AND THE REGISTRATION NO.
[OF THE STUDY/TRIAL] N/A.
MeSH Terms
Humans; Carcinoma, Hepatocellular; Male; Female; Liver Neoplasms; Middle Aged; Aged; Immune Checkpoint Inhibitors; Neoplasm Staging; Retrospective Studies; Adult
같은 제1저자의 인용 많은 논문 (4)
- Response to "Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma".
- Subcutaneous Adipose Tissue Accumulation is Associated With an Improved Prognosis in Patients With Hepatocellular Carcinoma.
- Invasive Bladder Cancer With Peritoneal Invasion and Rectal Involvement Causing Rectal, Bilateral Ureteral, and Common Bile Duct Obstruction Without a Retroperitoneal Mass: A Case Report.
- Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.